Levine J H, Nicholson W E, Orth D N
Proc Natl Acad Sci U S A. 1975 Jun;72(6):2279-83. doi: 10.1073/pnas.72.6.2279.
The present study was designed to determine whether the increase in rat renal ornithine decarboxylase (L-ornithine carboxy-lyase, EC 4.1.1.17) activity after cycloheximide administration was a primary effect on the kidney or was a secondary effect of adrenal or pituitary hormones released in response to the drug. Renal ornithine decarboxylase activity was reduced approximately 70% 1 hr after intraperitoneal administration of doses of cycloheximide that also inhibited renal protein synthesis by 68-95% within 1 hr. Protein synthesis began to recover by the second hour, accompanied by a rise in decarboxylase activity that reached a peak about six times greater than pretreatment values at 8 hr, then gradually declined to preinjection levels by 16 hr. Peak ornithine decarboxylase activity was directly proportional to cycloheximide doses up to 250 mug; larger doses, which almost abolished protein synthesis for 8 hr, where inhibitory. Plasma corticosterone rose rapidly after cycloheximide, reached a peak at 2 hr, then fell to baseline by 8 hr. Corticosterone response was also dose-dependent up to 250 mug, but larger doses were inhibitorymadrenalectomy did not reduce decarboxylase activity response to cycloheximide, nor did cortisol administration enhance it. Hypophysectomy greatly reduced baseline renal decarboxylase activity within 9 hr and all but abolished the increase in enzyme activity normally seen after cycloheximide administration to the intact rat. The hypophysectomized animal exhibited apparent increased sensitivity to cycloheximide, since a smaller dose of the drug caused a reduction in renal protein synthesis similar to that seen with a larger dose in the intact rat. As protein synthesis was recovering in the hypophysectomized animals, renal decarboxylase activity responded adequately to the injection of a crude pituitary extract. These data suggest that renal ornithine decarboxylase turnover is rapid, that baseline activity is.maintained by new protein synthesis, and that the increase in renal enzyme activity after cycloheximide is in larger part dependent upon pituitary hormone action.
本研究旨在确定给予环己酰亚胺后大鼠肾鸟氨酸脱羧酶(L-鸟氨酸羧基裂解酶,EC 4.1.1.17)活性的增加是对肾脏的直接作用,还是对药物产生反应后释放的肾上腺或垂体激素的间接作用。腹腔注射一定剂量的环己酰亚胺1小时后,肾鸟氨酸脱羧酶活性降低约70%,同时在1小时内肾蛋白合成也被抑制68 - 95%。蛋白合成在第二小时开始恢复,伴随脱羧酶活性升高,在8小时达到峰值,约为预处理值的6倍,然后在16小时逐渐降至注射前水平。鸟氨酸脱羧酶活性峰值与环己酰亚胺剂量成正比,直至250μg;更大剂量(几乎使蛋白合成在8小时内完全停止)则起抑制作用。环己酰亚胺给药后血浆皮质酮迅速升高,在2小时达到峰值,然后在8小时降至基线。皮质酮反应在剂量达250μg时也呈剂量依赖性,但更大剂量则起抑制作用。肾上腺切除并不降低对环己酰亚胺的脱羧酶活性反应,给予皮质醇也不增强该反应。垂体切除在9小时内使基础肾脱羧酶活性大幅降低,几乎消除了给予完整大鼠环己酰亚胺后通常出现的酶活性增加。垂体切除的动物对环己酰亚胺表现出明显的敏感性增加,因为较小剂量的药物导致肾蛋白合成减少,类似于完整大鼠中较大剂量药物所产生的效果。当垂体切除动物的蛋白合成恢复时,肾脱羧酶活性对注射粗制垂体提取物有充分反应。这些数据表明,肾鸟氨酸脱羧酶周转迅速,基础活性由新蛋白合成维持,且环己酰亚胺给药后肾酶活性增加在很大程度上依赖于垂体激素的作用。